secwatch.observer — SEC 8-K summary
======================================

Issuer:     Inhibikase Therapeutics, Inc. (IKT)
CIK:        0001750149
Form:       8-K
Filed at:   2026-11-10T21:28:20+00:00
Accession:  0001193125-26-455560
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Inhibikase Q3 2026 net loss $20.5M; cash $193.3M to fund IMPROVE-PAH through Part B readout
--------------------------------------------------------------------------------

- Q3 2026 net loss $20.5M ($0.10/share) vs $11.9M ($0.13/share) a year earlier; R&D rose to $15.0M from $7.6M and SG&A to $7.2M from $5.6M.
- Cash, cash equivalents and marketable securities were $193.3M at Sept 30, 2026, expected to fund operations through Part B topline, assuming full exercise of Series A and B warrants.
- Phase 3 IMPROVE-PAH has 28 country regulatory approvals and 79 of a planned 180 sites activated; Part A interim safety readout (n=50) planned for first half of 2027.
- July 2026: sold 25,000,000 shares to RA Capital via ATM for $50M gross; 18,030,000 later exchanged for pre-funded warrants. 140.3M shares and 60.6M pre-funded warrants outstanding.
- FDA granted Orphan Drug Designation for IKT-001 in July 2026; board added cardiologist Scott M. Wasserman, MD, CMO of Kailera Therapeutics, in October 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/0001193125-26-455560-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750149/000119312526455560/d95716d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-455560

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer